Turalio (_{-}nalfotamab mafodotin-ejfv) is a medication used to treat adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who have received at least one prior systemic therapy [1]. It is administered intravenously [2].
What is Turalio approved for?
Turalio is approved for adult patients with relapsed or refractory PTCL who have previously undergone at least one line of systemic treatment [1]. PTCL is a group of aggressive non-Hodgkin lymphomas [3].
How does Turalio work?
Turalio is an antibody-drug conjugate. It targets the CD25 protein, which is found on certain cancer cells. The antibody component delivers a chemotherapy agent directly to these cancer cells, helping to kill them [2].
What are the potential side effects of Turalio?
Common side effects of Turalio include fatigue, fever, rash, diarrhea, nausea, neutropenia (low white blood cell count), and edema (swelling) [2]. Patients may also experience peripheral neuropathy, a condition affecting the nerves that can cause numbness, tingling, or pain [2][4].
How is Turalio administered?
Turalio is given as an intravenous infusion by a healthcare professional [2]. The recommended starting dose is 3.0 mg/kg administered every three weeks [2].
What is the role of specialty pharmacies in dispensing Turalio?
Specialty pharmacies play a crucial role in managing and dispensing complex and high-cost medications like Turalio [5]. They provide comprehensive patient support services, including assistance with insurance authorization, financial assistance programs, and patient education on administration and side effect management [5]. Due to its administration requirements and potential side effects, Turalio is typically distributed through these specialized pharmacies to ensure patients receive proper guidance and support throughout their treatment [5].
What is the patent status for Turalio?
Information on the specific patent expiration dates for Turalio is available through resources that track pharmaceutical patents. DrugPatentWatch.com provides detailed patent information, including expiry timelines for various drugs [6].
What clinical data supports Turalio's use?
Turalio's approval was based on the results of a clinical trial that demonstrated its efficacy in patients with relapsed or refractory PTCL [1][7]. The trial assessed objective response rate and duration of response as key endpoints [7].
Where can I find more information about Turalio?
More information about Turalio, including prescribing information and patient resources, can be found on the manufacturer's website or through healthcare providers. DrugPatentWatch.com also offers data on patent exclusivity and potential generic entry timelines for medications like Turalio [6].
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/turalio-approved-treatment-adult-patients-relapsed-or-refractory-peripheral-t-cell-lymphoma
[2] https://www.drugpatentwatch.com/drugs/turalio
[3] https://www.cancer.org/cancer/types/lymphoma-non-hodgkins/about/peripheral-t-cell-lymphoma.html
[4] https://www.cancer.gov/publications/dictionaries/cancer-terms/def/peripheral-neuropathy
[5] https://www.ncpanet.org/about-ncpana/what-is-specialty-pharmacy/
[6] https://www.drugpatentwatch.com/
[7] https://www.nejm.org/doi/full/10.1056/NEJMoa1907783